Structure of an Fab-Protease Complex Reveals a Highly Specific Non-canonical Mechanism of Inhibition

Journal of Molecular Biology

Volumn 380, Issue 2, 2008, Pages 351-360

  Farady, Christopher J ^a   Egea, Pascal F ^b   Schneider, Eric L ^a   Darragh, Molly R ^a   Craik, Charles S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

antibody; protease inhibitor; serine protease; structure; substrate specificity

Indexed keywords

FAB ANTIBODY INHIBITOR; MATRIPTASE; PROTEINASE INHIBITOR;

ARTICLE; BINDING SITE; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; STRUCTURE ANALYSIS;

EID: 44949119318     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2008.05.009     Document Type: Article

References (46)

1. Rawlings N.D., Morton F.R., and Barrett A.J. MEROPS: the peptidase database. Nucleic Acids Res. 34 (2006) D270-D272
2. Roussel A., Mathieu M., Dobbs A., Luu B., Cambillau C., and Kellenberger C. Complexation of two proteic insect inhibitors to the active site of chymotrypsin suggests decoupled roles for binding and selectivity. J. Biol. Chem. 276 (2001) 38893-38898
3. Coussens L.M., Fingleton B., and Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295 (2002) 2387-2392
4. Turk B. Targeting proteases: successes, failures and future prospects. Nature Rev. Drug Discov. 5 (2006) 785-799
5. Rezacova P., Lescar J., Brynda J., Fabry M., Horejsi M., Sedlacek J., and Bentley G.A. Structural basis of HIV-1 and HIV-2 protease inhibition by a monoclonal antibody. Structure 9 (2001) 887-895
6. Puchi M., Quinones K., Concha C., Iribarren C., Bustos P., Morin V., et al. Microinjection of an antibody against the cysteine-protease involved in male chromatin remodeling blocks the development of sea urchin embryos at the initial cell cycle. J. Cell Biochem. 98 (2006) 335-342
7. Fukuoka Y., and Schwartz L.B. The B12 anti-tryptase monoclonal antibody disrupts the tetrameric structure of heparin-stabilized beta-tryptase to form monomers that are inactive at neutral pH and active at acidic pH. J. Immunol. 176 (2006) 3165-3172
8. Matias-Roman S., Galvez B.G., Genis L., Yanez-Mo M., de la Rosa G., Sanchez-Mateos P., et al. Membrane type 1-matrix metalloproteinase is involved in migration of human monocytes and is regulated through their interaction with fibronectin or endothelium. Blood 105 (2005) 3956-3964
9. Petersen H.H., Hansen M., Schousboe S.L., and Andreasen P.A. Localization of epitopes for monoclonal antibodies to urokinase-type plasminogen activator: relationship between epitope localization and effects of antibodies on molecular interactions of the enzyme. Eur. J. Biochem. 268 (2001) 4430-4439
10. Xuan J.A., Schneider D., Toy P., Lin R., Newton A., Zhu Y., et al. Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture. Cancer Res. 66 (2006) 3611-3619
11. Obermajer N., Premzl A., Zavasnik Bergant T., Turk B., and Kos J. Carboxypeptidase cathepsin X mediates beta2-integrin-dependent adhesion of differentiated U-937 cells. Expt. Cell Res. 312 (2006) 2515-2527
12. Sun J., Pons J., and Craik C.S. Potent and selective inhibition of membrane-type serine protease 1 by human single-chain antibodies. Biochemistry 42 (2003) 892-900
13. Farady C.J., Sun J., Darragh M.R., Miller S.M., and Craik C.S. The mechanism of inhibition of antibody-based inhibitors of membrane-type serine protease 1 (MT-SP1). J. Mol. Biol. 369 (2007) 1041-1051
14. List K., Szabo R., Molinolo A., Sriuranpong V., Redeye V., Murdock T., et al. Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation. Genes Dev. 19 (2005) 1934-1950
15. Bhatt A.S., Welm A., Farady C.J., Vasquez M., Wilson K., and Craik C.S. Coordinate expression and functional profiling identify an extracellular proteolytic signaling pathway. Proc. Natl Acad. Sci. USA 104 (2007) 5771-5776
16. Welm A.L., Sneddon J.B., Taylor C., Nuyten D.S., van de Vijver M.J., Hasegawa B.H., and Bishop J.M. The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. Proc. Natl Acad. Sci. USA 104 (2007) 7570-7575
17. Knappik A., Ge L., Honegger A., Pack P., Fischer M., Wellnhofer G., et al. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J. Mol. Biol. 296 (2000) 57-86
18. de Haard H.J., van Neer N., Reurs A., Hufton S.E., Roovers R.C., Henderikx P., et al. A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J. Biol. Chem. 274 (1999) 18218-18230
19. Perona J.J., and Craik C.S. Evolutionary divergence of substrate specificity within the chymotrypsin-like serine protease fold. J. Biol. Chem. 272 (1997) 29987-29990
20. Friedrich R., Fuentes-Prior P., Ong E., Coombs G., Hunter M., Oehler R., et al. Catalytic domain structures of MT-SP1/matriptase, a matrix-degrading transmembrane serine proteinase. J. Biol. Chem. 277 (2002) 2160-2168
21. 2+ sites in factor VIIa. J. Biol. Chem. 281 (2006) 24873-24888
22. Luthy J.A., Praissman M., Finkenstadt W.R., and Laskowski Jr. M. Detailed mechanism of interaction of bovine -trypsin with soybean trypsin inhibitor (Kunitz). I. Stopped flow measurements. J. Biol. Chem. 248 (1973) 1760-1771
23. Bode W., Schwager P., and Huber R. The transition of bovine trypsinogen to a trypsin-like state upon strong ligand binding. The refined crystal structures of the bovine trypsinogen-pancreatic trypsin inhibitor complex and of its ternary complex with Ile-Val at 1.9 Å resolution. J. Mol. Biol. 118 (1978) 99-112
24. Gebhard W., Tschesche T., and Fritz H. Biochemistry of aprotinin and aprotinin-like inhibitors. In: Barrett A.J., and Salvesen G. (Eds). Proteinase Inhibitors (1986), Elsevier, New York 55-152
25. Lawrence M.C., and Colman P.M. Shape complementarity at protein/protein interfaces. J. Mol. Biol. 234 (1993) 946-950
26. Huang M., Syed R., Stura E.A., Stone M.J., Stefanko R.S., Ruf W., et al. The mechanism of an inhibitory antibody on TF-initiated blood coagulation revealed by the crystal structures of human tissue factor, Fab 5G9 and TF.G9 complex. J. Mol. Biol. 275 (1998) 873-894
27. Krissinel E., and Henrick K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372 (2007) 774-797
28. Maskos K., Lang R., Tschesche H., and Bode W. Flexibility and variability of TIMP binding: X-ray structure of the complex between collagenase-3/MMP-13 and TIMP-2. J. Mol. Biol. 366 (2007) 1222-1231
29. Jenko S., Dolenc I., Guncar G., Dobersek A., Podobnik M., and Turk D. Crystal structure of Stefin A in complex with cathepsin H: N-terminal residues of inhibitors can adapt to the active sites of endo- and exopeptidases. J. Mol. Biol. 326 (2003) 875-885
30. Scheidig A.J., Hynes T.R., Pelletier L.A., Wells J.A., and Kossiakoff A.A. Crystal structures of bovine chymotrypsin and trypsin complexed to the inhibitor domain of Alzheimer's amyloid beta-protein precursor (APPI) and basic pancreatic trypsin inhibitor (BPTI): engineering of inhibitors with altered specificities. Protein Sci. 6 (1997) 1806-1824
31. Dennis M.S., and Lazarus R.A. Kunitz domain inhibitors of tissue factor-factor VIIa. II. Potent and specific inhibitors by competitive phage selection. J. Biol. Chem. 269 (1994) 22137-22144
32. Komiyama T., VanderLugt B., Fugere M., Day R., Kaufman R.J., and Fuller R.S. Optimization of protease-inhibitor interactions by randomizing adventitious contacts. Proc. Natl Acad. Sci. USA 100 (2003) 8205-8210
33. Kirchhofer D., Peek M., Li W., Stamos J., Eigenbrot C., Kadkhodayan S., et al. Tissue expression, protease specificity, and Kunitz domain functions of hepatocyte growth factor activator inhibitor-1B (HAI-1B), a new splice variant of HAI-1. J. Biol. Chem. 278 (2003) 36341-36349
34. Stoop A.A., and Craik C.S. Engineering of a macromolecular scaffold to develop specific protease inhibitors. Nature Biotechnol. 21 (2003) 1063-1068
35. Li P., Jiang S., Lee S.L., Lin C.Y., Johnson M.D., Dickson R.B., et al. Design and synthesis of novel and potent inhibitors of the type II transmembrane serine protease, matriptase, based upon the sunflower trypsin inhibitor-1. J. Med. Chem. 50 (2007) 5976-5983
36. Zhao G., Yuan C., Wind T., Huang Z., Andreasen P.A., and Huang M. Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1. J. Struct. Biol. 160 (2007) 1-10
37. Wu Y., Eigenbrot C., Liang W.-C., Stawicki S., Shia S., Fan B., et al. Structural insight into distinct mechanisms of protease inhibition by antibodies. Proc. Natl Acad. Sci. USA 104 (2007) 19784-19789
38. Takeuchi T., Shuman M.A., and Craik C.S. Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc. Natl Acad. Sci. USA 96 (1999) 11054-11061
39. Ho S.N., Hunt H.D., Horton R.M., Pullen J.K., and Pease L.R. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77 (1989) 51-59
40. Williams J.W., and Morrison J.F. The kinetics of reversible tight-binding inhibition. Methods Enzymol. 63 (1979) 437-467
41. Holton J., and Alber T. Automated protein crystal structure determination using ELVES. Proc. Natl Acad. Sci. USA 101 (2004) 1537-1542
42. Read R.J. Pushing the boundaries of molecular replacement with maximum likelihood. Acta Crystallogr. D 57 (2001) 1373-1382
43. Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D 50 (1994) 760-763
44. Evrard G.X., Langer G.G., Perrakis A., and Lamzin V.S. Assessment of automatic ligand building in ARP/wARP. Acta Crystallogr. D 63 (2007) 108-117
45. Adams P.D., Grosse-Kunstleve R.W., Hung L.W., Ioerger T.R., McCoy A.J., Moriarty N.W., et al. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr. D 58 (2002) 1948-1954
46. Lovell S.C., Davis I.W., Arendall III W.B., de Bakker P.I., Word J.M., Prisant M.G., et al. Structure validation by Calpha geometry: phi,psi and Cbeta deviation. Proteins: Struct Funct. Genet. 50 (2003) 437-450